NO952912L - En ny osteoblastisk proliferativ faktor - Google Patents

En ny osteoblastisk proliferativ faktor

Info

Publication number
NO952912L
NO952912L NO952912A NO952912A NO952912L NO 952912 L NO952912 L NO 952912L NO 952912 A NO952912 A NO 952912A NO 952912 A NO952912 A NO 952912A NO 952912 L NO952912 L NO 952912L
Authority
NO
Norway
Prior art keywords
new
proliferative factor
osteoblastic
bone
diseaese
Prior art date
Application number
NO952912A
Other languages
English (en)
Other versions
NO952912D0 (no
Inventor
Akira Kudo
Tohru Nakanishi
Masaharu Takigawa
Original Assignee
Hoechst Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan filed Critical Hoechst Japan
Publication of NO952912D0 publication Critical patent/NO952912D0/no
Publication of NO952912L publication Critical patent/NO952912L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO952912A 1994-07-22 1995-07-21 En ny osteoblastisk proliferativ faktor NO952912L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20125794A JP3738281B2 (ja) 1994-07-22 1994-07-22 新規な骨芽細胞増殖因子

Publications (2)

Publication Number Publication Date
NO952912D0 NO952912D0 (no) 1995-07-21
NO952912L true NO952912L (no) 1996-01-23

Family

ID=16437950

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952912A NO952912L (no) 1994-07-22 1995-07-21 En ny osteoblastisk proliferativ faktor

Country Status (14)

Country Link
US (1) US6080720A (no)
EP (1) EP0704219B1 (no)
JP (1) JP3738281B2 (no)
KR (1) KR100361717B1 (no)
AT (1) ATE206930T1 (no)
AU (1) AU693567B2 (no)
CA (1) CA2154403A1 (no)
DE (1) DE69523250T2 (no)
DK (1) DK0704219T3 (no)
ES (1) ES2161809T3 (no)
FI (1) FI953514A (no)
HU (1) HU217082B (no)
NO (1) NO952912L (no)
PT (1) PT704219E (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8936804B2 (en) * 2010-01-15 2015-01-20 Rutgers, The State University Of New Jersey Use of vanadium compounds to accelerate bone healing
EP2648718B1 (en) 2010-12-10 2019-05-08 Rutgers, the State University of New Jersey Implantable devices coated with insulin-mimetic agent composites and methods thereof
WO2013006798A1 (en) 2011-07-06 2013-01-10 University Of Medicine And Dentistry Of New Jersey Vandium compounds as therapeutic adjuncts for cartilage regeneration and repair
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
AU2460595A (en) * 1994-05-06 1995-11-29 Regeneron Pharmaceuticals, Inc. Methods based on the role of neurotrophin 3 in female reproduction

Also Published As

Publication number Publication date
HU9502202D0 (en) 1995-09-28
US6080720A (en) 2000-06-27
ATE206930T1 (de) 2001-11-15
DE69523250D1 (de) 2001-11-22
DE69523250T2 (de) 2002-07-04
EP0704219A2 (en) 1996-04-03
JP3738281B2 (ja) 2006-01-25
JPH0834744A (ja) 1996-02-06
EP0704219B1 (en) 2001-10-17
CA2154403A1 (en) 1996-01-23
HU217082B (hu) 1999-11-29
EP0704219A3 (en) 1997-12-10
KR100361717B1 (ko) 2003-07-07
DK0704219T3 (da) 2002-02-04
FI953514A (fi) 1996-01-23
AU2710595A (en) 1996-02-01
NO952912D0 (no) 1995-07-21
ES2161809T3 (es) 2001-12-16
FI953514A0 (fi) 1995-07-20
KR960003741A (ko) 1996-02-23
PT704219E (pt) 2002-03-28
HUT73185A (en) 1996-06-28
AU693567B2 (en) 1998-07-02

Similar Documents

Publication Publication Date Title
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
UA29505C2 (uk) Фармацевтична композиція для лікування і/або профілактики розрідження кістки і спосіб лікування і/або профілактики розрідження кістки у ссавців
HUT77380A (hu) Kombinált gyógyszerkészítmény alkalmazása sclerosis multiplex (MS) és más demielizáló állapotok kezelésére
DE4497905T1 (de) Pharmazeutische Zusammensetzung zur Prävention und Behandlung des Motion-Sickness-Syndroms
IL114683A0 (en) Combination treatment for inhibiting bone loss
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
MX9710252A (es) Utilizacion de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento.
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
ATE184788T1 (de) Idebenone-haltige zusammensetzungen zur behandlung von m. alzheimer
DE69420229T2 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE69426530D1 (de) Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz
NO952912D0 (no) En ny osteoblastisk proliferativ faktor
EP0744176A3 (en) Methods for inhibiting bone loss
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
NO20010984D0 (no) Anvendelse av R(+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol for behandling av søvnforstyrrelser
IT1276706B1 (it) Bicarbonati di derivati della 2,6-dimetilanilina, loro uso in terapia e composizioni farmaceutiche che li comprendono
TW224943B (en) The pharmaceutical composition for the stimulation of bone formation
AU639693B2 (en) Laser apparatus for treating bone and tooth tissue
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients
NO974941L (no) Ny anvendelse av (S)-adenosyl-L-metionin(SAMe)
SG64899A1 (en) Method and composition for treatment of patients having decompsated liver disease
IT1262567B (it) Pirrolidin-2-oni,loro preparazione,composizioni farmaceutiche che li contengono e loro uso in terapia.
PL54844Y1 (en) Dental surgeon's syringe

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application